Clinical Trial Update: Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose interleukin-2 for systemic lupus erythematosus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Low-dose Interleukin-2 (interleukin-2)

Snippet

Sponsor: Onur Boyman, MD | Conditions: Lupus Erythematosus, Systemic | Phase 2 | Status: COMPLETED